We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
TerrAscend Corp | TG:TED | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.74% | 0.67 | 0.655 | 0.685 | 0.67 | 0.67 | 0.67 | 104 | 20:59:59 |
RNS Number:5845S Tepnel Life Sciences PLC 27 November 2003 Tepnel Life Sciences PLC ('Tepnel' or 'the Company') Directors' Shareholdings Manchester, UK. 27 November 2003 ...The Company was notified today by Mr Ben Matzilevich, Chief Executive Officer, that in the recent placing he had purchased 434,783 ordinary shares of 1p each in the Company ("Ordinary Shares"), at a price of 11.5p per share. Following this purchase, Mr Matzilevich's total holding in Tepnel amounts to 934,783 Ordinary Shares, representing 0.71 per cent. of the issued share capital of the Company. The Company was notified today by Mr Gron Ffoulkes-Davies, Group Finance Director, that in the recent placing he had purchased 250,000 ordinary shares of 1p each in the Company ("Ordinary Shares"), at a price of 11.5p per share. Following this purchase, Mr Ffoulkes-Davies' total holding in Tepnel amounts to 650,000 Ordinary Shares, representing 0.49 per cent. of the issued share capital of the Company. For Further Information: Tepnel Life Sciences plc Ben Matzilevich, CEO Gron Ffoulkes-Davies, Finance Director 0161 946 2200 De Facto Communications Yvonne Alexander 020 7496 3300 Notes to Editors About Tepnel Life Sciences PLC Tepnel Life Sciences is a UK-based international life sciences instrumentation and services company with a 'tri-polar' strategy focused on providing the biomedical industry with high-throughput automated DNA purification systems, manual DNA purification kits and reagents, as well as scientific services for nucleic acid purification, drug analysis, genotyping and genetically modified foods. Tepnel Life Sciences was founded in 1992 to exploit DNA technology generated at UMIST (University of Manchester Institute of Science and Technology) and is quoted on the AIM segment of the London Stock Exchange (AIM: TED). More information on Tepnel can be found at www.tepnel.com. This information is provided by RNS The company news service from the London Stock Exchange END RDSUBVSROKRAUAA
1 Year TerrAscend Chart |
1 Month TerrAscend Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions